What is Sangamo Therapeutics, Inc.'s current stock price?

Sangamo Therapeutics, Inc. (SGMO) currently trades at USD 0.3001. Track real-time price changes and historical performance on AllInvestView.

What sector is Sangamo Therapeutics, Inc. in?

Sangamo Therapeutics, Inc. operates in the Health Care sector. AllInvestView lets you analyze sector allocation across your entire portfolio.

Sangamo Therapeutics, Inc.

🧾 Earnings Recap – Q3 2025

Sangamo Therapeutics reported significant advancements in its clinical pipeline for Fabry disease, highlighted by promising data from its STAAR study and a positive interaction with the FDA regarding its upcoming BLA submission.

Presented compelling clinical data from the STAAR study, showing durable benefits of ST-920, with a mean annualized eGFR slope of nearly 2 at 52 weeks across all patients.
FDA meeting confirmed agreement to use eGFR slope as an endpoint for an accelerated approval pathway, with plans for a BLA submission anticipated in early 2026.
Initiated the Phase I/II STAND study for chronic neuropathic pain, expanding Sangamo's reach into neurology.
Emphasized the strong safety profile and durable efficacy of ST-920, including encouraging cardiac data from treated patients.
Focused commitment to addressing unmet needs within the Fabry community, bolstered by patient engagement and feedback.

View full recap page

Sangamo Therapeutics, Inc. Analysis (SGMO)

United States Health Care Official Website Stock

Is Sangamo Therapeutics, Inc. a good investment? Sangamo Therapeutics, Inc. (SGMO) is currently trading at 0.3001 USD. Market analysts have a consensus price target of 3.75 USD. This suggests a potential upside from current levels.

Earnings Schedule: Sangamo Therapeutics, Inc. is expected to release its next earnings report on May 18, 2026. The market consensus estimate for Forward EPS is 0.03.

Investor FAQ

Does Sangamo Therapeutics, Inc. pay a dividend?

No, it does not currently pay a dividend.

What asset class is Sangamo Therapeutics, Inc.?

Sangamo Therapeutics, Inc. is classified as a Stock. You can compare it against 3 other assets in the "Related Symbols" list on this page.

When is the next earnings date?

The next earnings date is projected to be May 18, 2026. The company currently has a trailing EPS of -0.45.

Company Profile

Sangamo Therapeutics, Inc., a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; and SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A. Its preclinical development products focus on tauopathies, ALS/FTD, and huntington's diseases Sangamo Therapeutics, Inc. has collaborative and strategic partnerships with Biogen MA, Inc.; Kite Pharma, Inc.; Pfizer Inc.; Sanofi S.A.; Novartis Institutes for BioMedical Research, Inc.; Shire International GmbH; Dow AgroSciences LLC; Sigma-Aldrich Corporation; Genentech, Inc.; and Open Monoclonal Technology, Inc. The company was formerly known as Sangamo BioSciences, Inc. and changed its name to Sangamo Therapeutics, Inc. in January 2017. The company was incorporated in 1995 and is headquartered in Richmond, California.

Sangamo Therapeutics, Inc. SGMO Open Sangamo Therapeutics, Inc. in new tab

Sangamo Therapeutics, Inc.

Key Metrics

Growth

Estimates

DCF Valuation

DCF Assumptions

DCF Result

Explore Premium Features